The Trial (NCT00660309) was registered onClinicaltrials.govby the Sponsor, Novartis Pharmaceuticals. it to almost zero. == Conclusions == The relative resistance of the renal renin response to acute (irbesartan) and chronic (irbesartan and aliskiren) renin-angiotensin system blockade supports the concept of an activated renal renin-angiotensin system in diabetes, particularly at the level of the juxtaglomerular cell, and implies that diabetics require higher doses of renin-angiotensin system blockers to fully suppress the renal renin-angiotensin system. Keywords:chronic kidney disease, renin-angiotensin system, prorenin, juxtaglomerular cell == Introduction == Diabetes mellitus is the leading cause of nephropathy and end-stage renal disease in the Western world. Abnormalities involving renal perfusion and the renin-angiotensin system (RAS) appear to play an important pathogenic role, but the responsible mechanisms remain obscure [14]. A reduction in renal plasma flow (RPF) is usually common, accompanied by blunting of the renovascular response to angiotensin (Ang II) [14]. There is also an accentuated renal vasodilator response to angiotensin-converting enzyme (ACE) inhibition, which in turn corrects the blunting GSK-J4 of responsiveness to Ang II. All of these observations suggest activation of the RAS in patients with diabetes mellitus. As plasma renin often is usually reduced in such patients, the findings suggest that it is the intrarenal RAS that is activated GSK-J4 [1,5]. Despite being low, plasma renin is an impartial predictor of cardiovascular events in patients with diabetes [67]. The rise in plasma renin following RAS blockade is usually taken to be an indication of the degree of RAS blockade [8]. Importantly, the renin rise following acute exposure to increasing doses of the Ang II type 1 receptor blocker irbesartan in diabetics is usually blunted and slow as compared to nondiabetic healthy controls, and for a given renin rise a higher irbesartan dose was required in diabetics [1]. Yet, simultaneously, the RPF response to irbesartan was enhanced in diabetics vs. controls at all irbesartan doses tested [1]. Finally, the plasma levels of renins precursor, prorenin, are elevated in diabetes, and these elevated levels provide a strong indication of risk of the microvascular complications of this disease, i.e., GSK-J4 nephropathy and retinopathy [911]. To obtain a better understanding of the dysregulation of the RAS in diabetes, in the present study we carefully compared, in subjects with diabetes, the changes in plasma RAS parameters with the hemodynamic, renal and adrenal responses induced by blockade at the level of renin, ACE and the Ang II type 1 (AT1) receptor, both Rabbit Polyclonal to CD91 acutely and chronically. Doses of the 3 types of RAS blockers were chosen in such a manner that identical hemodynamic and renal responses could be expected, to rule out changes in plasma RAS parameters due to systemic or renal hemodynamic differences [1214]. In addition, subjects were exposed to a high-salt diet to minimize the contribution of the systemic RAS. == Methods == == Study protocol == Forty-three subjects with Type 2 GSK-J4 diabetes mellitus (29 men, 14 women) averaging 57 years of age GSK-J4 were studied on a high-sodium diet (Table 1). Fifty-eight percent were White and 30% were Black. All had hypertension, which was generally well controlled. Most were obese (weight 1054 kg, body mass index 34.81.2 kg/m2). After an outpatient evaluation, which included history, physical examination, screening chemistry, and hematology laboratory tests, all subjects were studied during.